LONDON, March 25, 2014 /PRNewswire/ --
On Monday, March 24, 2014, the
NASDAQ Composite ended at 4,226.39, down 1.18%, the Dow Jones
Industrial Average declined 0.16% to 16,276.69, and the S&P 500
closed at 1,857.44, down 0.49%. The losses were broad based as 8
out of 10 sectors ended the session in negative. The S&P 500
Health Care Sector Index finished the day at 666.18, down 1.41%,
and the same has fallen by 2.67% in the last one month.
Investor-Edge has initiated coverage on the following equities:
Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Alexion
Pharmaceuticals Inc. (NASDAQ: ALXN), Incyte Corp. Ltd (NASDAQ:
INCY) and Aastrom Biosciences Inc. (NASDAQ: ASTM). Free technical
research on MACK, ALXN, INCY and ASTM can be downloaded upon
signing up at:
http://www.investor-edge.com/457-register
Shares in Merrimack Pharmaceuticals Inc. closed at $5.25 on Monday, which is 1.32% lower than the
previous day's closing price of $5.32. A total of 2.03 million shares were traded
as compared with three months average volume of 1.64 million. The
company's shares oscillated between $4.91
and $5.40 during the trading session. Shares in Merrimack
Pharmaceuticals Inc. have advanced 5.21% in the last one month and
1.16% in the previous three months, while the same has declined
1.52% on YTD basis. The stock is trading above its 200-day moving
average. Merrimack Pharmaceuticals Inc.'s 50-day moving average of
$5.43 is above the 200-day moving
average of $4.61. Furthermore, the
stock is trading at an Relative Strength Index (RSI) of 47.70. Sign
up today to read free research on MACK at:
http://www.investor-edge.com/457-MACK-24Mar2014.pdf
Alexion Pharmaceuticals Inc.'s stock witnessed trading of 4.55
million shares on Monday, which is above the three months average
volume of 1.57 million shares. The stock ended the day at
$149.76, down 6.28% after trading
between $145.64 and $159.88. Shares in Alexion Pharmaceuticals Inc.
have surged 14.27% in the previous three months and 12.70% on YTD
basis. The stock is trading above its 200-day moving average.
Alexion Pharmaceuticals Inc.'s 50-day moving average of
$162.62 is above the 200-day moving
average of $125.26. Additionally,
shares of the company are trading at a PE ratio of 104.92 and at an
RSI of 38.22. Sign up today to read free research on ALXN at:
http://www.investor-edge.com/457-ALXN-24Mar2014.pdf
On Monday, Incyte Corp Ltd's stock plummeted 6.24%, finishing the
session at $55.70. The stock recorded
a trading volume of 3.43 million shares which is above the three
months average volume of 1.83 million. The company's shares
fluctuated between $53.23 and $59.77
during the session. Shares in Incyte Corp Ltd have gained 9.60% in
the previous three months and 10.01% on YTD basis. The stock is
trading above its 200-day moving average. Incyte Corp Ltd's 50-day
moving average of $64.14 is above the
200-day moving average of $42.48.
Moreover, shares of the company are trading at an RSI of 39.45.
Sign up today to read free research on INCY at:
http://www.investor-edge.com/457-INCY-25Mar2014.pdf
Aastrom Biosciences Inc.'s stock recorded a trading volume of 2.00
million shares, as compared with a three month average volume of
0.28 million shares. The stock ended Monday's session at
$5.08, down 21.73% after vacillating
between $4.89 and $6.24. Shares in Aastrom Biosciences Inc. have
rallied 27.96% in the previous three trading sessions, 50.30% in
the last one month and 57.28% on YTD basis. The stock is trading
above its 50-day moving average. Aastrom Biosciences Inc.'s 200-day
moving average of $5.40 is above the
50-day moving average of $3.68.
Further, the company's shares are trading at an RSI of 84.42. Sign
up today to read free research on ASTM at:
http://www.investor-edge.com/457-ASTM-24Mar2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://Investor-Edge.com
SOURCE Investor-Edge